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A gene bank ofMycobacterium bovis BCG DNA in Escherichia coli was constructed by cloning Sau3A-cleaved
mycobacterium DNA fragments into the lambda vector EMBL3. The expression of mycobacterial antigens was
analyzed by Western blotting with hyperimmune rabbit sera. Among 770 clones tested, several were found that
produced various mycobacterial antigens in low amounts, with concentrations generally close to the detection
limit. One particular clone was chosen for further investigation. This clone produced a 64-kilodalton (kDa)
antigen. By placing the lambda promoter PL in front of the structural gene of this antigen, an overproducing
E. coli strain was obtained. Rocket-line immunoelectrophoresis experiments showed that antigens cross-
reacting with the 64-kDa protein are present in a wide variety of mycobacteria and also in so-called purified
protein derivatives which are routinely used for skin tests. Preliminary experiments indicate the presence of
antibodies against the 64-kDa antigen in sera from tuberculosis patients.
Pathogenic mycobacteria contain a complex mixture of
antigens with varied chemical compositions (9, 10, 21). With
regard to their specificity, Stanford and Grange distinguished
four groups of mycobacterial antigens as follows: (i) antigens
common to all mycobacteria and often also found in Listeria,
Corynebacterium, and Nocardia spp.; (ii) common antigens
present only in slowly growing mycobacteria; (iii) common
antigens shared by fast growers and only present in these
bacteria; and (iv) species-specific antigens not found in other
species (22). Most studies on the specificity of soluble
mycobacterial antigens are based on experimental tech-
niques with immunoprecipitation in agarose and complex
mixtures of antigens derived from either ultrasonicated
bacteria or culture fluids.
Many attempts to isolate purified protein antigens from
these complex mixtures to produce specific and readily
standardizable antigens in sufficient amounts were unsuc-
cessful (9, 10, 21). The unavailability of purified antigens has
hampered a detailed study of the role of the individual
antigens in the immunological and pathological events during
mycobacterial infections. As a consequence, no satisfactory
rapid diagnostic test for the serodiagnosis of tuberculosis has
been developed, although many such attempts have been
made. The relatively crude and nonstandardizable antigens
employed in these studies resulted in nonreproducible tests,
a great deal of nonspecificity, or both (10).
A different approach to obtaining large amounts of well-
characterized, readily standardizable mycobacterial protein
antigens is the molecular cloning and expression of
mycobacterial DNA in a suitable host vector system. Clark-
Curtiss et al. (6) reported the establishment of gene libraries
of Mycobacterium vaccae, "Mycobacterium lufu," and My-
cobacterium leprae in Escherichia coli with a cosmid as a
vector. No expression of mycobacterial DNA was observed
in E. coli, unless the vector was provided with a strong
promoter. No antigen-expressing clones were found in a
limited number of M. Ieprae recombinants provided with a
transcription signal. More recently, Young et al. (27) re-
ported the cloning and expression of Mycobacterium tuber-
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culosis DNA in E. coli. By using the vector lambda gtll,
which is provided with a transcription and translation signal,
three different antigens were expressed as determined by
their reaction with three monoclonal antibodies.
In this paper, we report the cloning and expression of
Mycobacterium bovis BCG DNA in E. coli with the
bacteriophage lambda vector EMBL3. In addition, the char-
acterization of one immunogenic protein, expressed by E.
coli, is described.
MATERIALS AND METHODS
Bacterial strains, phages, and plasmids. The bacterial
strains used in this study are listed in Table 1. Strain Q359 and
the lambda vector EMBL3 (13) were kindly provided by R.
Koes. The plasmids pPLc236 (19) and pCI857 (20) were
kindly given by E. Remaut. Strain M1070 was used as a host
for latter plasmids or their derivatives.
Media and reagents. Mycobacteria were grown on Mid-
dlebrook 7H9 broth (DIFCO Laboratories, Detroit, Mich.)
with some minor modifications as follows. Four-tenths of a
gram of 0.4 g sodium citrate instead of 0.1 g, 1.5 g of
Na2HPO4 instead of 2.5 g, and 1.5 g of NaH2PO4 instead of
1.0 g was added per liter. NZYM medium or NZYM agar
(16) was used for growing E. coli K-12 cells. Antibiotic
supplements were previously described (25). All enzymes
used were from Boehringer GmbH, Mannheim, Federal
Republic of Germany, New England BioLabs, Beverly,
Mass., and P-L Biochemicals, St. Goar, Federal Republic of
Germany, and they were used according to the recommen-
dations of the manufacturer.
Anti-human and anti-rabbit immunoglobulins labeled with
horseradish peroxidase were kindly provided by A. M.
Hagenaars (Ryksinstitut voor Volksgezondheid en Milieu-
hygiene [RVM], Bilthoven, The Netherlands). Various prep-
arations of purified protein derivate (PPD) were kindly
provided by E. C. Beuvery (RVM, Bilthoven, The Nether-
lands). Goat anti-mouse total immunoglobulin peroxidase-
labeled conjugate was obtained from Nordic (Tilburg, The
Netherlands). The antisera against M. bovis BCG, 1739 and
1438, were raised by repeated intravenous immunization of
rabbits with disrupted cells of M. bovis BCG strain P3.
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TABLE 1. Bacterial strains
Strain Species Relevant properties Reference or origin
P3 M. bovis BCG BCG strain used as vaccine strain R. H. Tiesjema
in The Netherlands
7114 M. tuberculosis Clinical isolate This laboratory
H37Rv M. tuberculosis Reference strain This laboratory
4514 M. tuberculosis Clinical isolate This laboratory
3442 M. scrofulaceum Clinical isolate This laboratory
ATCC 14468 M. smegmatis Reference strain ATCCa
ATCC 25220 M. gastri Reference strain ATCC
1012 M. kansasii Clinical isolate This laboratory
3875 M. avium Clinical isolate This laboratory
ATCC 6841 M. fortuitum Reference strain ATCC
5544 M. africanum Clinical isolate This laboratory
8637 ADM Armadillo-derived mycobacterium F. Portaels (18)
LE392 E. coli K-12 hsrkhsm- P. Leder (16)
Q359 E. coli K-12 hsrk hSmk P2 lysogenic R. Koes (13)
1046 E. coli K-12 recA- hsrk hsmk L. van de Ploeg (4)
M1070 E. coli K-12 1046, carrying plasmid pCI857 This laboratory
a ATCC, American Type Culture Collection.
Another anti-BCG antiserum was obtained from DAKO
Laboratories, Copenhagen, Denmark. Murine monoclonal
antibodies from clone F47-10 were kindly provided by
A. H. J. Kolk (Royal Tropical Institute, Amsterdam, The
Netherlands).
DNA technology. DNA of M. bovis BCG was obtained as
follows. M. bovis BCG strain P3 was incubated in
Middlebrook 7H9 broth at 37°C. To make the mycobacterial
cells sensitive to lyzozyme, glycine was added in the late
exponential phase (24) to a final concentration of 1%, and
incubation was continued for 18 h. Cells from a 400-ml
culture were harvested, washed in saline, and suspended in
25% sucrose-0.05 M Tris-0.05 M EDTA (pH 8.0).
Lysozyme was added to a final concentration- of 1 mg/ml,
and the cells were incubated for 90 min at 37°C. Proteinase K
was added to 200 ,ug/ml, and the incubation at 37°C was
continued for 15 min. The cells were lysed by the addition of
sodium dodecyl sulfate to a final concentration of 5%. After
a 15-min incubation at 37°C, NaCl was added to a concen-
tration of 1 M, and DNA was extracted twice with phenol,
precipitated by ethanol, and further purified by CsCl density
gradient centrifugation as previously described (25).
Standard procedures were used for the preparation of
phage lambda and plasmid DNA, cleavage, ligation, trans-
formation, and packaging ofDNA (16). For cloning in phage
EMBL3, the vector DNA was cleaved with BamHI and
EcoRI. The small EcoRI-BamHI linker fragments were
removed by isopropanol precipitation (13). This procedure
prevented the stuffer fragment with BamHI ends to ligate
with the vector arms.
Immunological techniques. The expression of mycobacte-
rial antigens in E. coli K-12 was determined by the binding of
antibodies to proteins on nitrocellulose fractionated by so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis.
This so-called "Western blotting" was basically done as
described by Burnette (2), with some modifications as de-
scribed previously (25). For the detection of antigens in
lambda-infected cells, 20 ,ul of the lysates was applied into
lanes of polyacrylamide gel. Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis was done on 13%
acrylamide-containing gels as described by Laemmli (15).
Antisera used for Western blotting were absorbed with E.
coli K-12.
Soluble proteins of E. coli and mycobacteria were pre-
pared by breaking the cells with a French press, followed by
centrifugation for 5 min at 10,000 x g. Immunoelectropho-
resis techniques were performed as described by Axelsen
(1).
RESULTS
Construction of a gene bank of M. bovis BCG. The
bacteriophage lambda vector EMBL3 was used to construct
a gene bank of M. bovis BCG. Due to the lambda packaging
requirements, this vector allows the cloning of DNA frag-
ments with sizes of 9 to 22 kilobases (kb) (13). M. bovis BCG
DNA was partially cleaved with the restriction endonuclease
Sau3A, and fragments having sizes between 10 and 20 kb
were pooled. These fragments were ligated with BamHI-
cleaved EMBL3 DNA, and after in vitro packaging and
transduction into E. coli K-12 strain LE392, about 6,000
PFU of M. bovis DNA per ,ug were obtained. The same
efficiency was found by using the P2-lysogenic E. coli strain
Q359, indicating that virtually all plaque observed were from
recombinant DNA phages, as only recombinants are able to
grow on P2 lysogens (13). DNA from 12 randomly picked
plaques was analyzed by cleavage with the restriction en-
zyme Sall. All 12 restriction fragment patterns were dif-
ferent, showing that all of these clones contained various
mycobacterium Sau3A fragments.
Screening of recombinant DNA clones on the production of
mycobacterium antigens. Initially, an attempt was made to
select mycobacterial antigen-producing clones by an in situ
enzyme-linked immunoassay on plaques replicated onto
nitrocellulose filters (23, 26). More than 5,000 plaques were
screened by this method, and none of the recombinants
showed a significant positive signal with either the anti-M.
bovis BCG antiserum 1739 or the DAKO serum. This
number of recombinants should contain about 10 to 20
mycobacterium genome equivalents, as the maximal genome
size of M. bovis was estimated to be about 4,500 kb (3, 12).
These results indicate that the expression of M. bovis DNA
in E. coli K-12 is poor; therefore, a more sensitive assay was
used to detect antigens in the recombinant clones. In a
previous study (25), we found that Western blotting is quite
sensitive, with a lower detection limit of about 50 protein
molecules per E. coli cell. Therefore, Western blotting was
used to screen individual clones.
We screened 135 lysates by using the anti-M. bovis
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FIG. 1. Western blot of the primary screening of 16 recombinants of the M. bovis gene bank. Lanes 2 to 17 were loaded with 20 ,ul of E.
coli K-12 lysates containing approximately 2.5 jig of protein. Lane 1 was loaded with a lysate of M. bovis BCG containing about 7 p.g of
protein. The blot was developed with anti-M. bovis BCG rabbit antiserum 1739. Lane 8, A representative of phenotype A, showing an
antibody-binding protein antigen with an appaeent molecular mass of 64 kDa.
antiserum 1739 as well as the DAKO anti-M. bovis antiserum
to develop the nitrocellulose filters. As both antisera gave
identical results, the other lysates, 635 in number, were
screened only with serum 1739. Figure 1 is an example of the
screening procedure by immunoblotting. It shows the results
of the analysis of 16 individual recombinant clones, including
the one that produced a 64-kilodalton (kDa) protein that
reacted with antibodies in serum 1739.
In 21 of the 770 lysates tested, a band appeared, suggesting
the presence of the mycobacterial protein antigen. Accord-
ing to their mobility in sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis, 6 different antigenic phenotypes
were distinguished among these 21 clones (Table 2). Except
for phenotype A, the bands stained weakly and the antigen
concentration in these lysates was probably close to the
detection limit, suggesting a poor expression in E. coli. All
suspected positive clpnes were purified by replating, and
lysates from these clones were tested again on the produc-
tion of mycobacterial antigens. Only clones of the pheno-
types A, B, and C showed a reproducibly positive picture on
immunoblots. One clone, XRIB23, with phenotype A was
chosen for further investigation.
TABLE 2. Molecular sizes of M. bovis BCG proteins expressed
by EMBL3 recombinants in E. coli
Phenotype No. of clones Molecular size (kDa) Designation ofrepresentative clone
A 10 64 XRIB23
B 1 70 XRIB555
C 1 95 XRIB415
D 3 > 100 XRIB33
E 5 90 XRIB89
F 1 30 ARIB211
Subcloning of phenotype A clone ARIB23. The phenotype A
clone ARIB23 expresses a 64-kDa protein antigen designated
as antigen A. By cleavage of the DNA of XRIB23 with Sall,
the mycobacterium DNA insert in XRIB23 was estimated to
be about 19 kb. To construct an antigen A-overproducing
clone, XRIB23 was digested with EcoRI and subcloned into
the EcoRI site of the expression vector pPLc236. This vector
carries the left promoter, PL, of bacteriophage lambda. The
promoter can be fully repressed at 28°C when the ther-
molabile repressor product of the lambda C1857 gene is
functional, whereas strong transcription takes place at 42°C
(19). Two subclones, pRIB1000 and pRIB1001,- were ob-
tained that expressed the A antigen in the host at 28°C. Both
plasmids carried a 4.9-kb EcoRI fragment; however, the
orientation of this fragment in these two plasmids differed.
Consistently, cells containing only one of these plasmids,
pRIB1000, overproduced the antigen at 42°C (Fig. 2). To
further localize the DNA regions of pRIB1000 involved in
the expression of antigen A, deletion derivates of pRIB1000
were made by endonuclease digestion, followed by self-
ligation at low DNA concentrations (1 to 5 pg/ml) and
reintroduction into strain M1070. The physical map of
pRIB1000 and its various deletion derivatives are shown in
Fig. 3. The expression of antigen A by the various deletion
mutants was analyzed by Western blotting, and the results
(Fig. 3) indicate that the structLural gene of antigen A is
located within a 2.3-kb DNA segment on the pRIB1000 map
(Fig. 2) between the 1.5- and 3.8-kb coordinates. One
particular deletion mutant, pRIB1016, expressed an antigen
of only 38 kDa in size, suggesting the production of a
truncated protein.
Serological cross-reactivity of antigen A with other my-
cobacterial species. Immunoprecipitation by rocket-line im-
munoelectrophoresis is a powerful technique to detect the
presence of cross-reacting antigens in complex protein mix-
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FIG. 2. Expression of the A antigen by E. coli at 28°C (lanes 1 to 3) and 42°C (lanes 4 to 6). (A) Western blots of cell lysates of M1070 (lanes
3 and 6), M1070 carrying pRIB1000 (lanes 1 and 4), and M1070 carrying pRIB1001 (lanes 2 and 5). The blots were developed with anti-M. bov'is
BCG antiserum 1739. (B) Coomassie blue-stained polyacrylamide gels loaded with the same lysates as shown in panel A. S, Molecular weight
standards (Bio-Rad) as follows: lysozyme (14.3 kDa), soybean trypsin inhibitor (21.0 kDa), carbonic anhydrase (30.0 kDa), ovalbumin (43.0
kDa), bovine serum albumin (68.0 kDa), and phosphorylase B (94.0 kDa).
tures (1). Therefore, we checked whether antigen A precip-
itated in agarose by immunoelectrophoresis. The soluble
protein fraction of induced cultures of strain M1070 carrying
pRIB1000 gave rise to a number of precipitation lines in
rocket-line immunoelectrophoresis with serum 1438. One of
these lines could be identified as a precipitate of mycobac-
terium antigen, because only this line fused with a precipi-
tation line derived from a M. bovis BCG lysate. Rocket-line
immunoelectrophoresis was then used to determine whether
an antigen cross-reacting with antigen A was present in the
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soluble protein fraction of the following mycobacterium
species: M. tuberculosis (three strains), M. scrofulaceum,
M. smegmatis, M. gastri, M. kansasii, M. avium, M. fortu-
itum, M. africanum, and armadillo-derived mycobacterium.
In all of these bacteria, antigens cross-reacting with the A
antigen produced by E. coli were detected. Furthermore, we
analyzed the presence of cross-reacting antigens in PPDs
from M. tuberculosis, M. kansasii, M. fortuitum, M. avium
and M. marinulm. Rocket-line immunoelectrophoresis of all
of these PPDs showed the presence of cross-reacting anti-
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Sol I Sma IY4II Antigen production
/!. + ( 64 kd)
+ ( 64 kd)
+ ( 64 kd)
+ (64 kd)
+ ( 38 kd)
5 kb
FIG. 3. Physical map and expression of the mycobacterial 4.9-kb DNA segment in pRIB1000. The crosshatched parts represent the vector
pPLc236 DNA. The molecular masses (in kilodaltons) of the expressed proteins that bind antimycobacterium antibodies as detected by
Western blots is indicated on the right. The lambda promoter PL drives transcription from left to right on this map.
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FIG. 4. Rocket-line immunoelectrophoresis showing the cross-reacting components in various mycobacteria and PPDs with antigen A.
The sample gel S contained 400 ,ug of total soluble protein derived from induced cells of E. coli M1070(pRIB1000). The antiserum containing
gel AG contained immunoglobulin IG (final concentration, 1.2 mg/ml) from anti-M. bovis BCG serum 1739. Wells 1 and 2 each contained 5
,ug of PPD derived fron M. fortuitum and M. tuberulosis, respectively. Also shown are wells containing total soluble protein derived from
M. smegmatis strain (30 R±g [lane 3]), M. avium strain (4 ,ug [lane4]), M. tuberculosis strain H37Rv (5 ,ug [lane 5]), M. bovis BCG (1 ,ug [lane
6]), E. coli M10170 (7 ,ug [lane 7]), qnd induced cells of E. coli M10170(pRIB1000) (5 ,ug [lane 9]). As a control, 10 RI of distilled water was
applied to well 8. Note that the antigen A precipitate constitutes a continuous litie that is deflected when cross-reacting antigenic nmaterial is
present in a well.
gens.in each of them. An example of such a rocket-line
immunoelectrophoresis experiment is shown in Fig. 4. These
results indicate that epitopes of antigen A of M. bovis BCG
are Present in many different species and that they are a
constituent of various PPD preparations used for skin test-
ing,
Recently, A. H. J. Kolk selected a hybridoma culture that
produced a monoclonal antibody reacting with protein com-
ponents in a vari,ty of mycobacterial species. The molecular
mass of these proteins was approximately 65 kDa. There-
fore, we tested the reaction of these monoclonal antibodies
with" E. coli K-12 antigen A by Western blotting. These
monoclonal antibodies do react with the A antigen (Fig. 5).
Presence of antibodies in sera from tudterculous patients. As
a preliminary investigation to test the Value of the A antigen
for use in the serodiagnosis of tuberculosis, 16 sera from
tuberculosis patients were investigated for the presence of
antibb4ies against antigen A by Westerp blotting, with
protein obtained from an induced culture of M1070 that
carries pRIB1000. All of these sera reavted with the 64-kDa
component. No reaction was observed with any of four
control sera from humans with no history of a mycobacte-
rium infection. These humans were negative in the skin test
with M. tuberculosis-derived PPD.
DISCUSSION
A gene bank of M. bovis BCG in E. cdli was constructed
by insertion of partially Sau3A-cleaved M. bovis BCG DNA
into the bacteriophage vector EMBL3. As the mean size of
the inserts was ca. 15 kb, one might expept that the expres-
sion of cloned mycobacterial DNA depends almost entirely
on transcription and translation expression signals of the
mycobacterium DNA. Presently, no published information
is available about the nature of these signals in mycobacte-
rium. The most likely explanation for the relatively few
antigen-expressing clones found among the EMBL3 recom-
binants seems to be a difference between expression signals
in M. bovis and E. coli. Presumably the E. coli machinery for
protein synthesis does not recognize well the expression
signals of the distantly related bacterium M. bovis BCG.
This explanation is consistent with the recent findings of
Clark-Curtiss et al. on the expression of mycobacterium
DNA in E. coli (6). No complementation of various genetic
defects in E. coli was observed after screening for comple-
mentation by DNA from either M. vaccae, "Mycobac'terium
lufu," or M. leprae. However, the expression of a limited
number of genes was observed after linkage of M. leprae
DNA to a strong promoter (6).
In this study, 6 different phenotypes were observed among
the 21 antigen-producing M. bovis BCG recombinant clones.
The inability to reproducibly detect antigen production in the
clones with the phenotypes D, E, and F might be related to
the unstable nature of particular mycobacterial DNA seg-
ments in E. coli. Young et al. (27) reported the expression of
three M. tuberculosis antigens, reacting with monoclonal
antibodies against M. tuberculosis antigens, having molecu-
lar masses of 33, 18, and 16 kDa, respectively. The molec-
ular weights of all expressed M. bovis BCG antigens, except
phenotype F, observed in our study are higher than those
expressed by the M. tuberculosis-derived clones of Young et
al. Therefore, it is highly unlikely that any of the mycobac-
terium antigens obtained in this study are related to those
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FIG. 5. Reaction of monoclonal antibodies of hybridoma F47-10
with the A antigen produced by E. coli K-12. Lanes 1 and 2, Western
blot containing lysates derived from M1070 carrying pRIB1000 and
from M1070, respectively.
described by Young et al. Among the antigen-producing
clones obtained in this study, 10 were of one particular
phenotype, phenotype A. All of these produced a 64-kDa
protein antigen, designated antigen A. The structural gene of
antigen A was found to be located on a 4.9-kb EcoRI
fragment, and it was subcloned into the expression vector
pPLc236. In both orientations of this fragment in the vector,
an equally low level of production of the A antigen was
observed under noninducing conditions. Therefore, the ex-
pression of this antigen is controlled by a mycobacterial
promoter. This is the first example of a mycobacterial
promoter that functions in E. coli. One of the recombinant
plasmids, pRIB1000, expressed high levels of antigen A at
42°C, due to a strong transcription of the lambda PL pro-
moter. This overproducing strain enabled us to analyze the
specificity of antigen A. Antigen A was found to be present
in a variety of mycobacterial species; therefore, this com-
mon antigen is classified as a group i antigen according to the
classification of Stanford (22). This result is consistent with
the observation that antigen A reacts with monoclonal
antibodies derived from the hybridoma clone F47-10. These
antibodies react with protein antigens from several different
mycobacterial species, including M. leprae. The hybridoma
F47-10 was obtained from a mouse that had been immunized
with M. leprae antigens (A. Kolk, personal communication).
Crossed immunoelectrophoresis studies of Closs et al. (7)
have shown that virtually all antigens found in M. bovis BCG
are also found in M. tuberclulosis. Immunoblotting experi-
ments with polyvalent anti-M. tlbercullosis and anti-M.
bovis antisera, absorbed with cell extracts of either M. bolis
and M. tuberculosis, respectively, fully support the conclu-
sions of these authors (J. Thole, unpublished data). There-
fore, it will be difficult to clone genes expressing antigens
that are specific for either one of these organisms and which
are not found in other mycobacteria. However, such anti-
gens might be of great value as skin test reagents and in the
serodiagnosis of tuberculosis. Recently, Nagai et al. (17)
purified a protein, designated MPB70, that seems to be
present almost exclusively in certain strains of M. boI'is
BCG and only to a small extent in M. tuberc(ulosis (11). As
discussed by Grange (10), most other studies with partially
purified mycobacterial protein antigens have been frustrated
by their lack of specificity or by irreproducible results when
tested by others. Recent studies with monoclonal antibodies,
however, strongly suggest the existence of antigenic deter-
minants that are species specific (8, 14). In this preliminary
study, we screened the recombinant DNA clones with a
polyvalent anti-M. bovis BCG antiserum which was not
made specific by absorption with cell extracts of other
mycobacteria. Therefore, it is not surprising that a clone was
selected that produced a common mycobacterial protein
antigen. Future studies will be directed to select clones that
produce species-specific antigens or fusion proteins with
specific antigenic determinants, with monoclonal antibodies
as a probe. Furthermore, the use of expression vectors that
provide the recombinant DNA with transcriptional or trans-
lational signals or both seem to be a prerequisite for the
success of such studies.
It is well known that cell-mediated immunity plays a major
role in the immunity of humans against mycobacterial dis-
eases (5). Therefore, it is interesting to note that Emmrich
and Kaufmann have identified a number of human T-cell
clones that are stimulated by the A antigen produced by E.
coli. These T-cell clones were derived from a patient with
tuberculoid leprosy (F. Emmrich, J. E. R. Thole, J. D. A.
van Embden, and S. H. E. Kaufmann, submitted for publi-
cation). It is likely that M. leprae contains an immunogenic
protein that cross-reacts with antigen A and that causes a
cell-mediated immune response. Studies are now in progress
to purify antigen A and thus elucidate the possible role of
this antigen in the immunity of mycobacterial infections.
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